There are around 200 people in England who are eligible for this treatment More: NICE clears Opdivo for resected oesophageal or gastro-oesophageal junction cancer Source: News
read morePatients in the trial were those with unresectable hepatocellular carcinoma (HCC) who had not received systemic therapy treatment previously, and were not eligible for localised treatment More: Phase III trial shows AZ’s liver cancer combination improves overall survival Source: News
read moreFierce Pharma Asia—Takeda’s cell, gene therapy deals; BMS-BeiGene Abraxane brawl aliu Fri, 10/15/2021 – 05:47 More: Fierce Pharma Asia—Takeda's cell, gene therapy deals; BMS-BeiGene Abraxane brawl Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals